Educational paper: Do we need neonatal clinical pharmacologists?

European Journal of Pediatrics

Volumn 172, Issue 4, 2013, Pages 429-435

  Allegaert, Karel ^a   Langhendries, Jean Paul ^b   Van Den Anker, John N ^c,d,e  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b NICU ^*  (Belgium)

^c CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^d GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^e SOPHIA CHILDREN S HOSPITAL   (Netherlands)

Author keywords

Clinical pharmacology; Maturation; Newborn; Ontogeny; Pharmacodynamics; Pharmacokinetics

Indexed keywords

AMINOGLYCOSIDE; BEVACIZUMAB; BUMETANIDE; MEGALIN; MOTILIN;

BODY COMPOSITION; CLINICAL PHARMACOLOGY; DISTRIBUTION VOLUME; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG USE; GLOMERULUS FILTRATION RATE; HEALTH CARE PERSONNEL; HUMAN; INFANCY; KIDNEY TUBULE ABSORPTION; MINIMUM INHIBITORY CONCENTRATION; NEONATAL CLINICAL PHARMACOLOGIST; OFF LABEL DRUG USE; PATENT DUCTUS ARTERIOSUS; PATHOPHYSIOLOGY; PEDIATRICIAN; PHARMACODYNAMICS; PRIORITY JOURNAL; PROFESSIONAL KNOWLEDGE; RECEPTOR AFFINITY; RETROLENTAL FIBROPLASIA; REVIEW;

AMINOGLYCOSIDES; ANALGESICS, NON-NARCOTIC; ANTI-BACTERIAL AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; DOSE-RESPONSE RELATIONSHIP, DRUG; DUCTUS ARTERIOSUS, PATENT; HUMANS; INFANT, NEWBORN; PHARMACOLOGY, CLINICAL; RETINOPATHY OF PREMATURITY;

EID: 84876671618     PISSN: 03406199     EISSN: 14321076     Source Type: Journal    
DOI: 10.1007/s00431-012-1734-4     Document Type: Review

References (48)

1. Allegaert K, Verbesselt R, Naulaers G, van den Anker JN, Rayyan M, Debeer A, de Hoon J (2008) Developmental pharmacology: neonates are not just small adults. Acta Clin Belg 63:16-24
2. Anderson BJ, Allegaert K, Holford NH (2006) Population clinical pharmacology of children: modelling covariate effects. Eur J Pediatr 165:819-829
3. Anderson BJ, Allegaert K, Holford NH (2006) Population clinical pharmacology of children: general principles. Eur J Pediatr 165:741-746
4. Avery RL (2012) Bevacizumab (Avastin) for retinopathy of prematurity: wrong dose, wrong drug, or both? J AAPOS 16(1):2-4. doi:10.1016/j.jaapos.2011. 11.002
5. Ben-Ari Y (2012) Blocking seizures with the diuretic bumetanide: promises and pitfalls. Epilepsia 53:394-396
6. Benitz WE (2012) Patent ductus arteriosus: to treat or not to treat? Arch Dis Child Fetal Neonatal Ed 97:F80-F82
7. Casteels I, Cassiman C, van Calster J, Allegaert K Educational paper: retinopathy of prematurity. Eur J Pediatr. doi:10.1007/s00431-011-1610-7
8. D'Aloja E, Paribello F, Demontis R, Müller M (2011) Off-label drugs prescription in neonatology: a physician's duty or a medical hazardous attitude? J Matern Fetal Neonatal Med 24(Suppl 1): 99-100
9. Darlow BA, EllsAL, Gilbert CE, GoleGA,Quinn GE (2011) Are we there yet? Bevacizumab therapy for retinopathy of prematurity. Arch Dis Child Fetal Neonatal Ed. doi:10.1136/archdischild-2011-301148
10. De Cock RF, Allegaert K, Schreuder MF, Sherwin CM, de Hoog M, van den Anker JN, Danhof M, Knibbe CA (2012) Maturation of the glomerular filtration rate in neonates, as reflected by amikacin clearance. Clin Pharmacokinet 51:105-117
11. De Cock RF, Piana C, Krekels EH, Danhof M, Allegaert K, Knibbe CA (2011) The role of population PK-PD modelling in paediatric clinical research. Eur J Clin Pharmacol 67(Suppl 1):5-16
12. De Hoog M, Mouton JW, van den Anker JN (2005) New dosing strategies for antibacterial agents in the neonate. Semin Fetal Neonatal Med 10:185-194
13. De Hoog M, van Zanten BA, Hop WC, Overbosch E, Weisglas- Kuperus N, van den Anker JN (2003) Newborn hearing screening: tobramycin and vancomycin are not risk factors for hearing loss. J Pediatr 142:41-46
14. Desfrere L, Zohar S, Morville P, Brunhes A, Chevret S, Pons G, Moriette G, Rey E, Treluyer JM (2005) Dose-finding study of ibuprofen in patent ductus arteriosus using the continual reassessment method. J Clin Pharm Ther 30:121-132
15. De Wildt SN (2011) Profound changes in drug metabolism enzymes and possible effects on drug therapy in neonates and children. Expert Opin Drug Metab Toxicol 7:935-948
16. Dotta A, Braguglia A, Salvatori G (2011) Pharmacological research in neonatology. J Matern Fetal Neonatal Med 24(Suppl 1):44-46
17. Du W, Tutag Lehr V, Lieh-Lai M, Koo W, Ward RM, Rieder MJ, Van Den Anker JN, Reeves JH, Mathew M, Lulic-Botica M, Aranda JV (2012) An algorithm to detect adverse drug reactions in the neonatal intensive care unit: a new approach. J Clin Pharmacol. doi:10.1177/0091270011433327
18. Hirt D, van Overmeire B, Treluyer JM, Langhendries JP, Marguglio A, Eisinger MJ, Schepens P, Urien S (2008) An optimized ibuprofen dosing scheme for preterm neonates with patent ductus arteriosus, based on a population pharmacokinetic and pharmacodynamic study. Br J Clin Pharmacol 65:629-636
19. Hoppu K, Anabwani G, Garcia-Bournissen F, Gazarian M, Kearns GL, Nakamura H, Peterson RG, Sri Ranganathan S, de Wildt SN (2012) The status of paediatric medicines initiatives around the world - what has happened and what has not? Eur J Clin Pharmacol 68:1-10
20. Huth ME, Ricci AJ, Cheng AG (2011) Mechanisms of aminoglycoside ototoxicity and targets of hair cell protection. Int J Otolaryngol 2011:937861
21. Jacqz-Aigrain E (2011) Drug policy in Europe Research and funding in neonates: current challenges, future perspectives, new opportunities. Early Hum Dev 87(Suppl 1):S27-S30
22. Jadcherla SR, Klee G, Berseth CL (1997) Regulation of migrating motor complexes by motilin and pancreatic polypeptide in human infants. Pediatr Res 42:365-369
23. Kadambari S, Heath PT, Sharland M, Lewis S, Nichols A, Turner MA (2011) Variation in gentamicin and vancomcyin dosage and monitoring in UK neonatal units. J Antimicrob Chemother 66:2647-2650
24. Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE (2003) Developmental pharmacology - drug disposition, action, and therapy in infants and children. N Engl J Med 349:1157-1167
25. Langhendries JP, Maton P, François A, Marguglio A, Marion W, Smeets S, Philippet P (2010) Implementation of the intestinal micro flora in the early stage and adequate immunity later on. Arch Pediatr 17(Suppl 3):S110-S118
26. Langhendries JP, Battisti O, Bertrand JM, François A, Kalenga M, Darimont J, Scalais E, Wallemacq P (1998) Adaptation in neonatology of the once-daily concept of aminoglycoside administration: evaluation of a dosing chart for amikacin in an intensive care unit. Biol Neonate 74:351-362
27. Laughon MM, Benjamin DK Jr, Capparelli EV, Kearns GL, Berezny K, Paul IM, Wade K, Barrett J, Smith PB, Cohen- Wolkowiez M (2011) Innovative clinical trial design for pediatric therapeutics. Expert Rev Clin Pharmacol 4:643-652
28. Lopez-Novoa JM, Quiros Y, Vicente L, Morales AI, Lopez- Hernandez FJ (2011) New insights into the mechanism of aminoglycoside nephrotoxicity: an integrative point of view. Kidney Int 79:33-45
29. McIntyre J, Choonara I (2004) Drug toxicity in the neonate. Biol Neonate 86:218-221
30. Meißner U, Chakrabarty R, Topf HG, Rascher W, Schroth M (2012) Improved closure of patent ductus arteriosus with high doses of ibuprofen. Pediatr Cardiol. doi:10.1007/s00246-012- 0182-2
31. Mohamed AF, Nielsen EI, Cars O, Friberg LE (2012) Pharmacokinetic- pharmacodynamic model for gentamicin and its adaptive resistance with predictions of dosing schedules in newborn infants. Antimicrob Agents Chemother 56:179-188
32. National Patient Safety Agency, NHS (2010) Neonatal services urged to follow new gentamicin safety guidance. www.npsa. nhs.uk/corporate/news. Accessed 15 Feb 2012
33. Ramet J (2005) What the paediatricians need - the launch of paediatric research in Europe. Eur J Pediatr 164:263-265
34. Rao SC, Srinivasjois R, Hagan R, Ahmed M (2011) One dose per day compared to multiple doses per day of gentamicin for treatment of suspected or proven sepsis in neonates. Cochrane Database Syst Rev 2011:CD005091
35. Reed MD (2011) Reversing the myths obstructing the determination of optimal age- and disease-based drug dosing in pediatrics. J Pediatr Pharmacol Ther 16:4-13
36. Richey RH, Craig JV, Shah UU, Ford JL, Barker CE, Peak M, Nunn AJ, Turner MA (2012) The manipulation of drugs to obtain the required dose: systematic review. J Adv Nurs. doi:10.1111/j.1365-2648.2011.05916.x
37. Russell AB, Sharland M, Heath PT (2012) Improving antibiotic prescribing in neonatal units: time to act. Arch Dis Child Fetal Neonatal Ed 97:F141-F146
38. Sato T, Wada K, Arahori H, Kuno N, Imoto K, Iwahashi-Shima C, Kusaka S (2012) Serum concentrations of bevacizumab (Avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity. Am J Ophtalmol 153:327-333.e1
39. Shinwell ES, Eventov-Friedman S (2009) Impact of perinatal corticosteroids on neuromotor development and outcome: review of the literature and new meta-analysis. Semin Fetal Neonatal Med 14:164-170
40. Sutherland MR, Yoder BA, McCurnin D et al (2012) Effects of ibuprofen treatment on the developing preterm baboon kidney. Am J Physiol Renal Physiol. doi:10.1152/ajprenal.00216.2011
41. Tosse V, Pillekamp F, Verde P, Hadzik B, Sabir H, Mayatepek E, Hoehn T (2012) Urinary NT-proBNP, NGAL, and HFABP may predict hemodynamic relevance of patent ductus arteriosus in very low birth weight infants. Neonatology 101:260-266
42. Turner MA, Lewis S, Hawcutt DB, Field D (2009) Prioritising neonatal medicines research: UK medicines for children research network scoping survey. BMC Pediatr 9:50
43. Turner MA (2011) Neonatal drug development. Early Hum Dev 87:763-768
44. Van den Anker J (2009) Use of aminoglycosides in preterm neonates: a simple task? J Pediatr 154:935
45. Van den Anker JN, Allegaert K (2009) Individualized dosing of aminoglycosides in neonates: mission accomplished or work in progress? Eur J Clin Pharmacol 65:1159-1160
46. Van Overmeire B, Smets K, Lecoutere D, Van de Broek H, Weyler J, Degroote K, Langhendries JP (2000) A comparison of ibuprofen and indomethacin for closure of patent ductus arteriosus. N Engl J Med 343:674-681
47. Willing BP, Russell SL, Finlay BB (2011) Shifting the balance: antibiotic effects on host-microbiota mutualism. Nat Rev Microbiol 9:233-243
48. Zonnenberg I, de Waal K (2012) The definition of a haemodynamic significant duct in randomized controlled trials: a systematic literature review. Acta Paediatr 101:247-251